COSTA, FEDERICA
 Distribuzione geografica
Continente #
NA - Nord America 922
EU - Europa 809
AS - Asia 493
AF - Africa 15
Continente sconosciuto - Info sul continente non disponibili 2
SA - Sud America 2
Totale 2.243
Nazione #
US - Stati Uniti d'America 901
CN - Cina 283
SE - Svezia 193
IE - Irlanda 187
IT - Italia 185
SG - Singapore 142
DE - Germania 71
FI - Finlandia 62
TR - Turchia 53
FR - Francia 30
AT - Austria 21
CA - Canada 20
CZ - Repubblica Ceca 14
CI - Costa d'Avorio 10
RO - Romania 10
IN - India 9
GB - Regno Unito 8
BE - Belgio 7
NL - Olanda 6
ES - Italia 4
LT - Lituania 4
BG - Bulgaria 2
BR - Brasile 2
EU - Europa 2
HK - Hong Kong 2
KH - Cambogia 2
NG - Nigeria 2
SC - Seychelles 2
SM - San Marino 2
BY - Bielorussia 1
CH - Svizzera 1
DK - Danimarca 1
EG - Egitto 1
IL - Israele 1
IR - Iran 1
MX - Messico 1
Totale 2.243
Città #
Chandler 218
Dublin 187
Singapore 104
Parma 93
Ann Arbor 74
Ashburn 72
Shanghai 56
Dearborn 54
New York 49
Boardman 41
Izmir 38
Nanjing 36
Beijing 35
Princeton 32
Shenyang 23
Helsinki 21
Vienna 21
Wilmington 20
Marseille 18
Toronto 16
Munich 15
Bremen 13
Hebei 13
Jinan 13
Kocaeli 13
Kunming 13
Nanchang 13
Brno 12
Abidjan 10
Jiaxing 10
Milan 10
San Mateo 10
Redmond 9
Focsani 8
Tianjin 8
Brussels 7
Los Angeles 7
Woodbridge 7
Zhengzhou 7
Changsha 6
Hangzhou 6
Hefei 6
Modena 6
Fairfield 5
Palermo 5
Chongqing 4
Dallas 4
Des Moines 4
Houston 4
Madrid 4
Norwalk 4
Rio Saliceto 4
Seattle 4
Torino 4
Ahmedabad 3
Düsseldorf 3
Gorgonzola 3
Ottawa 3
Redwood City 3
Reggio Emilia 3
Santa Clara 3
Taizhou 3
Washington 3
Bologna 2
Cornaredo 2
Deiva Marina 2
Guangzhou 2
Haikou 2
Hong Kong 2
Lagos 2
London 2
Mestre 2
Paris 2
Phnom Penh 2
Pune 2
Rho 2
Rockville 2
Rome 2
Segrate 2
Tampa 2
Turku 2
Vignola 2
Xian 2
Ankara 1
Atlanta 1
Augusta 1
Borås 1
Bucharest 1
Buffalo 1
Cairo 1
Castelfranci 1
Castelfranco Emilia 1
Charlotte 1
Chengdu 1
Chicago 1
Denver 1
Edinburgh 1
Frankfurt am Main 1
Fremont 1
Jacksonville 1
Totale 1.560
Nome #
Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target 104
Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20 103
The Proteasome and Myeloma-Associated Bone Disease 94
Bone marrow Dikkopf-1 levels are a new independent risk factor for progression in patients with smouldering myeloma 88
Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation 86
Possible targets to treat myeloma-related osteoclastogenesis 84
CD14+CD16+ monocytes are involved in daratumumab-mediated myeloma cells killing and in anti-CD47 therapeutic strategy 83
Oncolytic virotherapy and microenvironment in multiple myeloma 81
Bone Marrow DKK-1 Levels in Smoldering Multiple Myeloma Patients: A New Independent Risk Factor for Progression 80
LENALIDOMIDE INCREASES HUMAN DENDRITIC CELL MATURATION MODULATING BOTH MONOCYTE DIFFERENTIATION AND MESENCHYMAL STROMAL CELL INHIBITORY PROPERTIES 80
Improved scaffold biocompatibility through anti-Fibronectin aptamer functionalization 77
Myeloma Cells Deplete Bone Marrow Glutamine and Inhibit Osteoblast Differentiation Limiting Asparagine Availability 77
DEPENDENCE ON GLUTAMINE UPTAKE OF MYELOMA CELLS DELINEATES A NEW ATTRACTIVE THERAPEUTIC STRATEGY 75
PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients 73
EXPRESSION OF CD38 AND ECTOENZYMES OF THE ADENOSINERGIC PATHWAYS IN MYELOMA BONE NICHE: A RATIONAL BASIS FOR THE USE OF DARATUMUMAB TO TARGET OSTEOCLAST FORMATION IN MULTIPLE MYELOMA 71
Bone marrow CD14+ cells show different transcriptional profiles in Multiple Myeloma (MM) as compared to smoldering MM and MGUS: overexpression of IL21R and its involvement in osteoclastogenesis 70
ADENOSINE IN THE MYELOMA BONE MARROW NICHE: IMMUNE CHECKPOINT AND KEY PLAYER IN DISEASE PROGRESSION 70
Adenosine Generated in the Bone Marrow Niche Through a CD38-Mediated Pathway Correlates with Progression of Human Myeloma. 69
Lenalidomide increases human dendritic cell maturation in multiple myeloma patients targeting monocyte differentiation and modulating mesenchymal stromal cell inhibitory properties 69
IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts 67
Oncolytic Virotherapy in Multiple Myeloma: A Possible Alternative Role of Bovine Viruses 66
The link between bone microenvironment and immune cells in multiple myeloma: Emerging role of CD38 66
Expression Profile of CD38 and Related Ectoenzymes in Myeloma Bone Niche: A Rational Basis for the Use of Daratumumab to Inhibit Osteoclast Formation and Activity 66
Il mieloma multiplo nell'era dei nuovi farmaci. Patogenesi 65
Lenalidomide Increases Human Dendritic Cell Maturation in Multiple Myeloma Modulating Both Monocyte Differentiation and Mesenchymal Stromal Cell Inhibitory Properties through Ikaros and Casein Kinase 1 Degradation, Respectively 61
CD38 Expression by Myeloma Cells and Its Role in the Context of Bone Marrow Microenvironment: Modulation by Therapeutic Agents 60
Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies 56
PD-L1/PD-1 axis in multiple myeloma microenvironment and a possible link with CD38-mediated immune-suppression 55
Transcriptional and proteomic profiles of bone marrow CD14+ cells in multiple myeloma (MM) compared to smoldering MM and MGUS: overexpression of Interleukin (IL)-21 receptor and its involvement in MM-induced osteoclastogenesis 54
Overexpression of Pro-Osteoclastogenic Cytokine Receptors and Chemokines By Bone Marrow CD14(+) Monocytes of Multiple Myeloma (MM) Patients As Compared to Smoldering MM (SMM) and Monoclonal Gammopathy of Uncertain Significance (MGUS): Role of Interleukin(IL)-21 Receptor/IL-21 Axis in MM-Induced Osteoclastogenesis 51
CD38: A target for immunotherapeutic approaches in multiple myeloma 49
Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NAD+ 39
Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response 29
Totale 2.318
Categoria #
all - tutte 9.832
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 9.832


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020180 0 0 0 0 8 47 37 9 31 32 11 5
2020/2021198 13 4 4 4 37 6 9 15 40 28 9 29
2021/2022164 5 5 10 14 3 0 28 10 14 11 8 56
2022/2023805 90 93 64 70 63 86 29 49 223 7 22 9
2023/2024333 16 30 10 6 23 104 36 17 9 14 11 57
2024/2025238 15 39 41 107 36 0 0 0 0 0 0 0
Totale 2.318